Last reviewed · How we verify
AZM Group
Azithromycin targets bacterial ribosomes to inhibit protein synthesis.
Azithromycin targets bacterial ribosomes to inhibit protein synthesis. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute otitis media.
At a glance
| Generic name | AZM Group |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Macrolide antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Azithromycin binds to the 50S subunit of bacterial ribosomes, preventing the translocation of peptidyl-tRNA and thereby inhibiting protein synthesis. This action is bacteriostatic, meaning it prevents the growth and replication of bacteria, rather than killing them outright.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute otitis media
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children (PHASE3)
- MSC for Treatment of Interstitial Lung Disease After Allo-HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |